<abstract xmlns="http://www.w3.org/1999/xhtml">In order to investigate the potential of nanostructured lipid carriers for efficient and targeted delivery of curcumin, the pharmacokinetic parameters of curcumin-loaded nanostructured lipid carriers (Cur-NLC) were evaluated in rats after a single intraperitoneal dose of Cur-NLC. In addition, the anticancer activity of Cur-NLC against human lung adenocarcinoma A549 cells was verified by a cellular uptake study, and a cytotoxicity and apoptosis assay. Bioavailability of Cur-NLC was better than that of native curcumin (<italic>p</italic> > 0.01), as seen from the area under the plasma concentration-time curve (<italic>AUC</italic>), maximum plasma concentration (<italic>C</italic>max), mean residence time (MRT) and total plasma clearance (CLz/F). Cur-NLC has a more obvious lung-targeting property in comparison with native curcumin. Cur-NLC showed higher anticancer activity <italic>in vitro</italic> against A549 cells than native curcumin (<italic>IC</italic>50 value of 5.66 <italic>vs.</italic> 9.81 mg L−1, respectively). Meanwhile, Cur-NLC treated A549 cells showed a higher apoptosis rate compared to that of native curcumin. These results indicate that NLC is a promising system for the delivery of curcumin in the treatment of lung adenocarcinoma.</abstract>

In order to investigate the potential of nanostructured lipid carriers for efficient and targeted delivery of curcumin, the pharmacokinetic parameters of curcumin-loaded nanostructured lipid carriers (Cur-NLC) were evaluated in rats after a single intraperitoneal dose of Cur-NLC. In addition, the anticancer activity of Cur-NLC against human lung adenocarcinoma A549 cells was verified by a cellular uptake study, and a cytotoxicity and apoptosis assay. Bioavailability of Cur-NLC was better than that of native curcumin (p > 0.01), as seen from the area under the plasma concentration-time curve (AUC), maximum plasma concentration (Cmax), mean residence time (MRT) and total plasma clearance (CLz/F). Cur-NLC has a more obvious lung-targeting property in comparison with native curcumin. Cur-NLC showed higher anticancer activity in vitro against A549 cells than native curcumin (IC50 value of 5.66 vs. 9.81 mg L−1, respectively). Meanwhile, Cur-NLC treated A549 cells showed a higher apoptosis rate compared to that of native curcumin. These results indicate that NLC is a promising system for the delivery of curcumin in the treatment of lung adenocarcinoma.

Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers

Department of Pharmacy, The Second People’s Hospital of Hefei

Acta Pharmaceutica

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

In order to investigate the potential of nanostructured lipid carriers for efficient and targeted delivery of curcumin, the pharmacokinetic parameters of...

Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers

Data publikacji: 30 sie 2017

Zakres stron: 357 - 371

Przyjęty: 19 mar 2017

DOI: https://doi.org/10.1515/acph-2017-0021

Słowa kluczowe
curcumin, nanostructured lipid carriers, pharmacokinetic, anticancer effects, lung adenocarcinoma

© 2017 Fengling Wang et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Pharmacokinetic studies and anticancer activity of curcumin-loaded nanostructured lipid carriers

Data publikacji: 30 sie 2017

Zakres stron: 357 - 371

Przyjęty: 19 mar 2017

DOI: https://doi.org/10.1515/acph-2017-0021

Słowa kluczowecurcumin, nanostructured lipid carriers, pharmacokinetic, anticancer effects, lung adenocarcinoma

© 2017 Fengling Wang et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Słowa kluczowe
curcumin, nanostructured lipid carriers, pharmacokinetic, anticancer effects, lung adenocarcinoma